Cargando…

Intermittent treatment of BRAF(V600E) melanoma cells delays resistance by adaptive resensitization to drug rechallenge

Patients with melanoma receiving drugs targeting BRAF(V600E) and mitogen-activated protein (MAP) kinase kinases 1 and 2 (MEK1/2) invariably develop resistance and face continued progression. Based on preclinical studies, intermittent treatment involving alternating periods of drug withdrawal and rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kavran, Andrew J., Stuart, Scott A., Hayashi, Kristyn R., Basken, Joel M., Brandhuber, Barbara J., Ahn, Natalie G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944661/ https://www.ncbi.nlm.nih.gov/pubmed/35290123 http://dx.doi.org/10.1073/pnas.2113535119

Ejemplares similares

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
por: Myrdal, Caitlyn N., et al.
Publicado: (2020)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
por: Vidarsdottir, Linda, et al.
Publicado: (2020)

BRAF V600 mutations and pathological features in Japanese melanoma patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report
por: Dooley, Andrew J., et al.
Publicado: (2016)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma
por: Smith, Lorey K., et al.
Publicado: (2022)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
por: Kocovski, Linda, et al.
Publicado: (2015)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
por: Stagno, Anna, et al.
Publicado: (2021)

Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis
por: Priantti, Jonathan N., et al.
Publicado: (2023)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
por: Zepeda-Lopez, Priscilla Denise, et al.
Publicado: (2016)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
por: Banzi, Maria, et al.
Publicado: (2016)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten−/− melanoma
por: Scortegagna, Marzia, et al.
Publicado: (2013)

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
por: Roller, Devin G., et al.
Publicado: (2015)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets
por: Improta, Giuseppina, et al.
Publicado: (2013)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
por: Krepler, Clemens, et al.
Publicado: (2016)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
por: Sevilla, Arrate, et al.
Publicado: (2020)

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
por: Meevassana, Jiraroch, et al.
Publicado: (2022)

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas
por: Rebecca, Vito W., et al.
Publicado: (2023)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Resensitizing AMPA receptors
por: Short, Ben
Publicado: (2019)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
por: Gonzalez-Cao, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fq5d8u223h7u2bmfggjntbcif5